STATEMENTS OF CASH FLOWS (USD $)
 9 Months Ended 12 Months Ended 181 Months Ended 12 Months Ended 172 Months Ended
Sep. 30, 2011
Sep. 30, 2010
Dec. 31, 2009
Sep. 30, 2011
Sep. 30, 2011
Common Stock
Sep. 30, 2011
Preferred Stock
Sep. 30, 2011
Prior to Merger
Sep. 30, 2011
After Merger
Dec. 31, 2010
Restated Amount
Dec. 31, 2010
Restated Amount
OPERATING ACTIVITIES                    
Net loss $ (2,777,528) $ (846,374) $ (2,463,751) $ (28,394,040)         $ (2,575,284) $ (25,576,751)
Plus non-cash charges to earnings:                    
Stock compensation expense     1,452,231 2,018,280           2,018,280
Depreciation and amortization 4,778 4,515 3,534 87,745         6,049 85,107
Purchase R&D - Clear Image       3,309,514           3,309,514
Stock issued for services         5,598,222 270,000        
Expenses paid by third parties       57,134           57,134
Contribution of services by officer and employees       799,154           799,154
Services by officer and employees paid for with non-cash consideration       167,500           167,500
Compensation cost for option price reduction       50,000           50,000
Amortization debt discounts                 125,000 125,000
Amortization of options and common stock issued for services       1,775,577           1,775,577
Allowance for doubtful accounts       50,900           50,900
Gain on extinguishment of debt       (10,398)           (10,398)
Write-off of Notes Receivable       14,636           14,636
Write-off of Notes Payable       (8,239)           (8,239)
Write-off of organizational costs       3,196           3,196
Write-off of zero value investments       785,418           785,418
Write-off of leasehold improvements and computer equipment       2,006           2,006
Compensation costs for stock options and warrants granted to non-employees       1,205,015           1,205,015
Change in working capital accounts:                    
(Increase) decrease in receivables from related parties     (4,395) (94,105)         (25,205) (94,105)
Increase in other assets 86,896 1,800   91,291            
(Increase) decrease in goodwill       (23,276)           (23,276)
(Increase) decrease in other receivables       (457,266)         (274,361) (450,938)
Increase (decrease) in accrued salaries and consulting   (70,542) (696,655) (21,172)         (215,224) (21,172)
Increase (decrease) in accrued interest 43,334 7,166   185,834         1,323 92,500
Increase (decrease) in accounts payable and accrued liabilities (139,332)   (333,294) 2,276,337         1,188,405 2,413,169
Total operating activities (2,426,002) (903,435) (1,156,289) (10,534,513)         (1,208,524) (8,108,511)
INVESTING ACTIVITIES                    
Purchase of equipment and furnishings (157,621) (230,376) (39,685) (1,046,723)         (782,375) (889,102)
Investment in syringe patent development (19,000)   (25,000) (54,000)           (35,000)
Investment in Ives Health Company       (251,997)           (251,997)
Investment in The Health Club       (10,000)           (10,000)
Total investing activities (176,621) (230,376) (64,685) (1,362,720)         (782,375) (1,186,099)
FINANCING ACTIVITIES                    
Loans from shareholders       15,707         1,800 15,707
Repayment of loans from shareholders       (8,005)           (8,005)
Repayments of Promissory Notes     (133,429) 57,325           57,325
Common stock subscribed     (512,500) 546,500           546,500
Sale of preferred stock for cash:       (1,000)           (1,000)
Proceeds from sale of common stock to third party investors             574,477 5,743,214    
From exercise of stock options and warrants 1,465,820 358,386 558,701 3,783,988         96,200 2,318,168
Common Stock issued for payment of debt 427,921     805,764         366,166 366,166
Less: Issue Costs       (102,318)           (102,318)
Derivative Liability   164,761                
Debt Discount   (60,267)                
Convertible debentures issued for cash 439,598 169,500   782,921           355,000
Payment of exclusive license note payable       (100,000)           (100,000)
Treasury Stock       (969)         (969) (969)
Total financing activities 2,535,910 1,124,552 1,283,406 12,097,604         1,993,188 9,561,694
Minority interest                   (197,567)
Minority interest       (197,567)            
Change in cash (66,713) (9,259) 64,432 2,804         2,289 2,289
Cash at beginning of period 69,517 67,228 4,796           67,228 67,228
Cash at end of period 2,804 57,969 67,228 2,804         69,517 69,517
Supplemental disclosure of cash flow information:                    
Cash paid for interest and taxes during the period                   57,571
Non-cash financing and investing activities:                    
Investment in Globe Joint Venture                   (637,566)
20 to 1 reverse stock split                   138,188
Common stock subscriptions                   69,800
Capitalized compensation cost for options granted                   $ 1,487,700